Letolizumab (BMS-986004) is a dimer antibody construction targeting CD40L, which is produced to express mutant IgG1 lacking effector function, including Fc binding and complement fixation. Letolizumab reduces rejection, thromboembolism and prolongs the survival time.
| CAS Number | 1450981-87-9 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
[4] Ankita Srivastava. Indian J Dermatol. Itolizumab in Psoriasis
| Related TNF Receptor Products |
|---|
| Chilob7/4
Chilob7/4 is a chimeric agonist anti-CD40 IgG1 antibody that can be used for tumor-related studies. |
| VIB4920
VIB4920 is a fusion protein that binds to CD40L on activated T cells and blocks the interaction of CD40L with CD40-expressing B cells and other possible binding substrates. |
| ABBV-428
ABBV-428 is a bispecific antibody targeting CD40/Mesothelin and can be used in studies related to solid tumors. |
| TNF-α (31-45), human
TNF-α (31-45), human is a potent NF-kB pathway activator. |
| LEESGGGLVQPGGSMK
LEESGGGLVQPGGSMK, a proteolysis peptide, is a component of Infliximab. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
